The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Official Title: A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma
Study ID: NCT01455493
Brief Summary: This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
, Phoenix, Arizona, United States
, Newport Beach, California, United States
, Orange, California, United States
, Palo Alto, California, United States
, San Francisco, California, United States
, Denver, Colorado, United States
, New Haven, Connecticut, United States
, Boca Raton, Florida, United States
, Orlando, Florida, United States
, West Palm Beach, Florida, United States
, Hinsdale, Illinois, United States
, Indianapolis, Indiana, United States
, Louisville, Kentucky, United States
, Scarborough, Maine, United States
, Baltimore, Maryland, United States
, Boston, Massachusetts, United States
, Boston, Massachusetts, United States
, Voorhees, New Jersey, United States
, New York, New York, United States
, New York, New York, United States
, Durham, North Carolina, United States
, Winston-salem, North Carolina, United States
, Oklahoma City, Oklahoma, United States
, Abington, Pennsylvania, United States
, Pittsburgh, Pennsylvania, United States
, Salt Lake City, Utah, United States
, Seattle, Washington, United States
, Milwaukee, Wisconsin, United States
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR